Oncko
10 employees on LinkedIn · 3 known investors
Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms. The company serves oncology drug developers seeking to identify efficacious combination regimens for cancer indications.
Founders & leadership
AD
BG
Bill GrossmaninCo-founder, Strategic Advisor
Investors · 3
Competitors · 7
by search overlap
Oncusp Therapeutics6 shared keywordsOnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
Oncosenx5 shared keywordsOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
OncoC44 shared keywordsOncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders. It advances its pipeline through internal R&D and external partnerships, including a collaboration with BioNTech to develop and commercialize gotistobart.
Onkure Therapeutics Inc4 shared keywordsOnKure Therapeutics is a clinical-stage biopharmaceutical company developing PI3Kα pan-mutant selective inhibitor medicines for the treatment of breast cancer and vascular anomalies. Its focus is on selective, allosteric small-molecule oncology therapeutics.
OncoHealth4 shared keywordsOncoHealth provides oncology-specific utilization management and virtual supportive care services for health plans, employers, and their members with cancer. Its offerings include OneUM for prior authorization workflows and Iris, a virtual service giving members 24/7 access to oncology-trained nurses, mental health therapists, and dietitians.
Octant Bio4 shared keywordsOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Onc4 shared keywordsOnc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making. Its products serve pharma companies with Phase IB/II clinical trial decisions and predict immunotherapy response and outcomes for metastatic lung cancer patients.
Companies competing with Oncko for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Oncko do?
- Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms. The company serves oncology drug developers seeking to identify efficacious combination regimens for cancer indications.
- Who founded Oncko?
- Oncko was founded by Atray Dixit, Bill Grossman.
- Who are Oncko's investors?
- Oncko's investors include Adverb Ventures, Illumina Ventures, Tenmile.